Songli Pharmaceutical: The weight loss effect of ASC47 combined with semaglutide in obese subjects is relatively increased by as much as 56.2% compared to semaglutide alone.

Gelesis Pharmaceuticals announced on the Hong Kong Stock Exchange that the combination of ASC47 and semaglutide compared to semaglutide alone resulted in a relative increase in weight loss of up to 56.2% in obese subjects.